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Abstract
Objectives: To examine sex differences in disease profiles, management, and survival at 1 and 5 years after is-
chemic stroke (IS) among people with atrial fibrillation (AF).
Methods:We performed a systematic literature search of reports of AF at IS onset according to sex. We undertook
an individual participant data meta-analysis (IPDMA) of nine population-based stroke incidence studies con-
ducted in Australasia, Europe, and South America (1993–2014). Poisson regression was used to estimate wom-
en:men mortality rate ratios (MRRs). Study-specific MRRs were combined using random effects meta-analysis.
Results: In our meta-analysis based on aggregated data from 101 studies, the pooled AF prevalence was 23%
(95% confidence interval [CI]: 22%–25%) in women and 17% (15%–18%) in men. Our IPDMA is of 1,862 IS-AF
cases, with women (79.2 – 9.1, years) being older than men (76.5 – 9.5, years). Crude pooled mortality rate was
greater for women than for men (1-year MRR 1.24; 1.01–1.51; 5-year 1.12; 1.03–1.22). However, the sex difference
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was greatly attenuated after accounting for age, prestroke function, and stroke severity (1-year 1.09; 0.97–1.22;
5-year 0.98; 0.84–1.16). Women were less likely to have anticoagulant prescription at discharge (odds ratio
[OR] 0.94; 95% CI: 0.89–0.98) than men when pooling IPDMA and aggregated data.
Conclusions: AF was more prevalent after IS among women than among men. Among IS-AF cases, women
were less likely to receive anticoagulant agents at discharge; however, greater mortality rate in women was
mostly attributable to prestroke factors. Further information needs to be collected in population-based studies
to understand the reasons for lower treatment of AF in women.
Keywords: atrial fibrillation; ischemic stroke; sex differences
Background
Worldwide, the number of men having atrial fibrilla-
tion (AF) is nearly twice that of women.1,2 However,
women tend to have more severe AF symptoms and
are at a higher risk of death and cardiovascular dis-
ease.1,2 In a comprehensive meta-analysis3 of 30 studies
with 4,371,714 participants, AF was associated with a
larger relative risk (RR) of stroke in women than in
men (1.47, 95% confidence interval [CI]: 1.18–1.83).
This might be explained by the presence of more
comorbidities in women with AF than in men.3 There-
fore, factors such as hypertension, older age, larger
atrial dimensions, valvular disease, and cardiovascular
remodeling have been suggested as plausible mecha-
nisms leading to an apparent greater risk of stroke in
women.4
Similarly, significant disparities in the burden of
stroke between men and women have also been identi-
fied by the Global Burden of Disease (GBD) 2013
Study, with men having consistently greater incidence
of ischemic stroke (IS) than women.5 However, the
proportion of stroke-related deaths was greater in
women than in men. In the INternational STRoke oUt-
Comes sTudy (INSTRUCT), which included 16,957
participants from 13 population-based incidence stud-
ies, the greater mortality rate in women was largely at-
tributable to age, but other important factors including
stroke severity, presence of AF, and prestroke depen-
dency also contributed to this disparity.6 These findings
highlight the importance of investigating differences
between women and men in the management and out-
comes after stroke among participants with IS and AF.
Recently, the GBD 2016 investigators emphasized
the importance of quantifying the attributable burden
of AF for stroke.7 Indeed, in a large-scale registry
study of 10,528 participants with IS in Canada, AF
has been associated with an increased risk of death
and severe disability. Older age and increased stroke
severity were found to explain most of the association
between AF and outcomes. However, observational ev-
idence on how sex modifies the association between
AF and outcomes is scarce.8–11 In this study, we per-
formed a systematic review of existing evidence and
meta-analysis using individual participant data (IPD)
of nine studies from the INSTRUCT.11 Our aims
were to outline the evidence for sex differences in dis-
ease profiles, management factors, and outcomes in
participants with IS and AF.
Methods
Systematic review/meta-analysis
of aggregated data of published studies
We included all studies in which AF was reported at the
time of IS presentation, and were stratified according
to sex. We also included participants aged at least 18
years, of any race with a clinical or imaging (computed
tomography or magnetic resonance imaging) diagnosis
of first-ever or recurrent IS. There were no language
restrictions.
A comprehensive search strategy (in the Supplemen-
tary Data)—developed in consultation with a univer-
sity librarian, neurologists, and epidemiologists—was
used to address the unique features and indexing
of each of the two electronic databases (MEDLINE
and Embase), which were searched from inception to
December 20, 2018. The systematic review was reported
following Meta-analysis Of Observational Studies in
Epidemiology guidelines.12 In addition to searching
for original studies, the reference lists of any relevant
reviews appearing in their reports were examined. Refer-
ence screening, data extraction, and quality assessment
using Newcastle-Ottawa scale (NOS)13 were performed
by J.L. and S.C.Y. Disagreements were resolved by a
third author (X.W.).
The main outcomes of interest were the sex differ-
ences in the proportion of AF among participants
with IS; also of interest were the stroke severity and
functional outcomes (assessed by modified Rankin
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scale [mRS], Barthel Index (BI), or recurrent stroke) in
participants with IS and AF.
The data were pooled using random effects models
where data were available. The degree of heterogeneity
was calculated using the I2-index. We also used meta-
regression to assess whether sex differences in AF prev-
alence were modified by age.
Meta-analysis of IPD
The INSTRUCT is an IPD database of long-term
outcomes after first-ever stroke comprising 13 ‘‘gold
standard’’ population-based stroke incidence stud-
ies,14,15 which have greater internal validity and less
selection bias than hospital-based studies.16 The de-
tails of the design of INSTRUCT have been described
elsewhere.6,17,18
This analysis focused on participants with IS and AF
in the INSTRUCT, and included nine studies whose in-
vestigators have agreed to participate (Supplementary
Table S1).19–27 These studies were conducted in
Australia, New Zealand, Brazil, Greece, Sweden, Por-
tugal, Italy, and Estonia between 1993 and 2014. This
study was approved by the Tasmanian Health andMed-
ical Human Research Ethics Committee (H0014861).
All of the participating studies had signed informed
consent and approval from their respective local ethics
committees.
Outcome measurement
Outcomes of stroke included all-cause mortality and
functional outcomes up to 5 years after stroke. The de-
tails of study outcomes of the INSTRUCT have been
described elsewhere.6,18 Measures of mortality rate
at 1 year were available among all nine studies,
whereas those at 5 years were available among 5five
of nine studies. Mortality rate was obtained from na-
tional death registries (the studies from Melbourne,
Perth, Orebro, and Tartu) or the combination of hos-
pital records, death certificates, or participant follow-
ups (remaining studies: Joinville, Arcadia, Porto,
Auckland, L’Aquila).
Six studies had functional outcomes measurement
assessed by the mRS (score range 0–5) or BI (score
range 0–20) at 1 year, whereas only three studies had
5-year functional outcomes after stroke. The mRS or
BI scores were assessed by research nurses or attending
physicians face to face or by telephone (Supplementary
Table S1). Poorer functional outcome was defined as
mRS >2 or BI <20 at 1 or 5 years after stroke, mRS
was used if both were available.
Study factors
The presence of AF was self-reported by participants
in two studies and was confirmed by ECG or medical
record in the remaining seven studies (Supplementary
Table S1). The methods for ascertainment of other study
factors are described elsewhere.6 For each study, a wide
range of factors that might contribute to sex differences
were recorded.28 These were (1) sociodemographics,
(2) prestroke health (dependence, comorbidities, and
health behaviors), (3) stroke-related factors (stroke se-
verity and year of stroke occurrence), and (4) treat-
ment and management.
Statistical analysis
Because of the inconsistency of covariate measure-
ments between studies from different populations, we
used the two-stage method of analysis proposed for
IPD meta-analysis29 using the same approach demon-
strated in previous publications from INSTRUCT, in-
cluding for mortality6 and functional outcome.18
The first stage involved building study-specific crude
and adjusted models to estimate women:men mortality
rate ratio (MRR) or RR of having poorer functional
outcomes for women compared with men. For mor-
tality outcome, we used Poisson regression with the
logarithm of the number of person-years at risk of
dying within that period entered as an offset.30 For
functional outcome, multivariable log-binomial re-
gression was performed.
Within each study, we assessed the confounding
role31 of covariates in the association between sex and
each outcome. The following rules were applied to de-
termine the confounders in the study-specific multivar-
iable models: (1) the covariate was associated with
mortality, (2) the covariate was associated with sex,
and (3) the inclusion of the covariate in a model with
only sex changed the magnitude of the sex coefficient
by ‡10%.31 Adjustment was done for each variable
separately and then for all confounding factors in mul-
tivariable analyses, but with age, stroke severity, and
prestroke function (where available) were forced into
a final fully adjusted model. Within each study, statisti-
cal interactions were assessed by a test of statistical sig-
nificance of a sex· covariate product term. Covariates
chosen for the test include age, stroke severity, and pre-
stroke function, and all other significant confounding
factors. To further examine the robustness of our find-
ings, we also tested interaction effects between sex and
participant-level covariates including stroke type, age
at stroke onset, and the year of stroke occurrence.
Wang et al.; Women’s Health Report 2020, 1.1
http://online.liebertpub.com/doi/10.1089/whr.2020.0029
192
For the second stage of the analysis, unadjusted and
adjusted study-specific estimates were pooled in sepa-
rate random effects meta-analyses, so that the pooled
values could be compared to determine the effect of ad-
justment. Heterogeneity was evaluated using Q statis-
tics and I2 statistics. Meta-regression was used to
identify the sources of statistically significant heteroge-
neity among study-level characteristics.
Pooling meta-analysis of aggregated data
and meta-analysis of IPD
Where possible, IPD meta-analysis and meta-analysis
based on aggregated data from the literature were
pooled using random effects models and odds ratios
(ORs) were reported. Two-sided p-values of £0.05
were deemed statistically significant. All statistical ana-
lyses used Stata, version 12.1.
Results
Systematic review/meta-analysis
of aggregated data of published studies
Of 15,127 references obtained after execution of the
search strategy, 3,057 remained after screening titles
and abstracts for relevance (Supplementary Fig. S1).
One hundred and one studies (n = 2,298,873 partici-
pants) that satisfied the eligibility criteria were included
in the review (Supplementary Table S2). Four stud-
ies32–35 were defined as low quality with scores <5
using NOS. Begg’s regression tests identified no evi-
dence of publication bias ( p= 0.07).
The pooled proportion of AF in participants with IS
was 23% (95% CI: 22%–25%) in women and 17%
(15%–18%) in men, the I2 was 98.6% and 96.8%, re-
spectively (Supplementary Figs. S2 and S3). Among
participants with IS and AF, women were much older
than men. However, meta-regression demonstrated
that sex differences in AF prevalence after stroke
were consistent with increasing age ( p = 0.243, Supple-
mentary Fig. S4).
In five out of six studies with data on stroke severity
by sex, women with AF had more severe IS than men at
IS onset, as assessed by National Institutes of Health
Stroke Scale (NIHSS), mRS or CHADS2 score (Supple-
mentary Table S3). Antiplatelet therapy by sex at IS
onset or discharge was reported in a lower proportion
among women with AF than among men (9 of 11 stud-
ies; Supplementary Table S4). More women with AF
than men had a history of hypertension at IS onset in
all five studies, whereas fewer women with AF reported
a history of diabetes than men in four of five of the
studies (Supplementary Table S5). Women with AF
tended to have poorer outcomes than men after IS
(6 of 6 studies; Supplementary Table S6).
Meta-analysis of IPD using the INSTRUCT
There were 8,645 participants from the nine studies
with a mean age of 72.6 years and 51.8% (4,480)
being women (Supplementary Table S7). The propor-
tion of AF varied across studies ranging from 6.2% to
42.3% in women and from 4.4% to 34.4% in men (Sup-
plementary Table S7). The pooled proportion of AF
was 26.6% in women and 20.8% in men. The preva-
lence was higher in women than in men, even after
allowing the differences explained by age (RR 1.15,
95% CI: 1.06–1.25) (Fig. 1).
Table 1 shows the baseline characteristics of partici-
pants with IS who have AF (n= 1,862), further stratified
by sex in each study (Supplementary Tables 8 and 9).
Women were older, more likely to be living in institu-
tions, and more functionally dependent before stroke
than men. More women than men had a history of pe-
ripheral vascular disease or transient ischemic attack
(TIA), whereas men were more often smokers and
drinkers. Women sufferedmore severe stroke thanmen.
Among participants with IS who have AF, women
tended to have more severe stroke (NIHSS score,
NIHSS >7) than men (Supplementary Fig. S5), al-
though this difference did not reach statistical signifi-
cance. Women were less likely to have history of
ischemic heart disease (0.87, 0.76–0.99). There was
no significant sex difference in comorbidities including
TIA (RR 0.78, 95% CI: 0.58–1.05), hypertension
(RR 1.07, 95% CI: 0.99–1.17), and diabetes (RR 1.05,
95% CI: 0.73–1.49) (Supplementary Fig. S6). There
were no significant differences in receiving anticoagu-
lant (RR 0.94, 95% CI: 0.61–1.46; Fig. 2), antihyperten-
sive, and antiplatelet agents (Supplementary Fig. S7).
The survival rate using pooled IPD for people with AF
and IS was 51.7% in women and 58.9% in men at 1 year
(9 studies) and 31.9% in women and 36.8% in men at 5
years (5 studies; Supplementary Table S10). Women
were 24% more likely than men to have died within
1 year in crude analyses (RR 1.24, 95% CI: 1.01–1.51),
without evidence of heterogeneity (I2= 34; Q= 16.3;
p= 0.146; Fig. 3 and Supplementary Tables S11 and
S12). However, after adjustment for confounders includ-
ing age, the strength of the association was attenuated
and the difference in mortality rate was no longer statis-
tically significant (RR 1.09, 0.97–1.22). In crude analyses
of 5-year mortality rate, women had a trend to be 12%
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more likely than men to die after stroke (MRR 1.12, 95%
CI: 1.03–1.22; Fig. 3). After adjusting for covariates
including age, severity and prestroke disability, there
was no difference in survival between men and women
(MRR 0.98, 95% CI: 0.84–1.16; Fig. 3). When the models
were adjusted for age, severity, and prestroke dependency
separately, we found that the coefficient of the sex differ-
ence in RR was attenuated most with adjustment for age
(Supplementary Table S13).
The proportion of poor functional outcome using the
pooled IPD among people with IS and AF was 41.3%
(women) and 31.5% (men) at 1 year (6 studies) and
35.5% (women) and 23.4% (men) at 5 years (3 studies;
Table 1). At 1 year, women were 61% more likely than
men to have poor functional outcomes in crude analyses
(RR 1.61, 95%CI: 1.27–2.04) without evidence of hetero-
geneity (I2= 0%; p= 0.642). However, after adjusting for
confounders including age, the magnitude of the dif-
ference was attenuated (RR 1.15, 95% CI: 0.93–1.43)
(Fig. 4). At 5 years, women were not significantly dif-
ferent from men in terms of having poor functional
outcomes in crude (RR 1.12, 95% CI: 1.03–1.22)
and adjusted (RR 0.98, 95% CI: 0.84–1.16) analyses.
When the models were adjusted for age, severity,
and prestroke dependency separately, we found that
the coefficient of the sex difference in RR was attenu-
ated most with adjustment for age (Supplementary
Tables S14–S17).
Pooled meta-analysis of aggregated
data and IPDMA
Women were less likely to receive anticoagulant agents
at discharge (age-adjusted pooled OR women vs. men
0.94, 95% CI: 0.89–0.98, Fig. 2). Women were 23%
more likely than men to have died within 1 year in
crude analyses (OR 1.23, 95% CI: 1.00–1.51), with-
out evidence of heterogeneity (I2 = 34; Q = 16.3;
p = 0.146). However, after adjustment for confound-
ers including age, the strength of the association was
attenuated and the difference in mortality rate was
no longer statistically significant (OR 1.09, 0.97–
1.22) (Fig. 3).
Discussion
In this systematic review and meta-analysis, we found
that AF was more prevalent after IS among women
than among men. Among participants with IS who
have AF, women were older than men, they tend to
have more severe strokes, more often have a history
of hypertension and diabetes, but less often had ische-
mic heart disease and TIA. Women were less likely to
be prescribed anticoagulant agents at discharge from
hospital. The greater mortality rate and poorer func-
tional outcome after stroke in women were mostly attrib-
utable to their differences in clinical profile, including
advanced age, greater stroke severity, and prestroke func-
tional limitations.
Our IPD data provide further evidence that age was
the most important contributor to the sex difference in
poor prognosis among participants with IS who have
AF.6,36,37 This could be explained by several reasons.
First, given that AF increases with age and that women
have greater life expectancy, we would expect an increas-
ing proportion of women with AF as the population
ages.38 Furthermore, women are more likely than men
to experience AF-related symptoms, to have significantly
FIG. 1. The pooled proportion of AF for women and men in the included studies of individual patient
data meta-analysis. AF, atrial fibrillation.
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higher heart rates during AF, and a less favorable response
to treatment.39 Piccini et al. reported that women have
higher stroke risk despite equal anticoagulant use.40 It
has also been observed that women with AF have more
advanced atrial fibrosis than men. These sex differences
are more pronounced with a history of IS, suggesting
that sex may play a role in fibrotic remodeling of the
left atrium and subsequent stroke.41,42 An added factor43
to consider, which is rarely included in population-level
studies, is hormone replacement therapy (HRT). HRT
and particularly conjugate equine estrogens have been
linked to increased risk of AF as well as stroke and, of
course, HRT use also increases with age so could poten-
tially contribute to the age effect.
With respect to evidence-based medications for sec-
ondary prevention, out data show women were less
Table 1. Characteristics of Nine Included Cohort Studies
in Patients with Ischemic Stroke and Atrial Fibrillation,
by Sex
Characteristic
Women,
n (%) Men, n (%) p
Sociodemographics
Mean (SD) Age (nine studies) 79.2 (9.1) 76.5 (9.5) <0.001
Marital status (three studies)
Single/widowed 54 (37.5) 121 (65.8) <0.001
Married 88 (61.1) 60 (32.6)
Unknown 2 (1.4) 3 (1.6)
Education level (four studies)
£Grade 12 144 (53.7) 213 (58.4) 0.352
>Grade 12 86 (32.1) 98 (26.9)
Unknown 38 (14.2) 54 (14.8)
Social class (four studies)
Professional 61 (24.7) 50 (14.9) <0.001
Nonmanual 55 (22.3) 106 (31.6)
Manual 94 (38.1) 78 (23.2)
Unknown 37 (15.0) 102 (30.4)
Prestroke health
In an institution (three studies)
Yes 16 (11.4) 28 (15.0) 0.607
No 123 (87.9) 157 (84.0)
Unknown 1 (0.7) 2 (1.1)
Modified Rankin Score (mRS; four studies)
0–2 138 (87.3) 184 (81.1) 0.253
3–5 10 (6.3) 23 (10.1)
Unknown 10 (6.3) 20 (8.8)
Barthel Index score (BI; three studies)
20 74 (52.9) 83 (44.4) 0.316
<20 23 (16.4) 36 (19.3)
Unknown 43 (30.7) 68 (36.4)
Mean (SD) mRS 0.7 (1.0) 1.1 (1.1) 0.002
Mean (SD) BI 18.6 (3.7) 18.8 (3.1) 0.338
Medical history
Hypertension (nine studies)
Yes 457 (60.0) 712 (64.7) 0.085
No 295 (38.7) 371 (33.7)
Unknown 10 (1.3) 17 (1.6)
Ischemic heart disease (nine studies)
Yes 248 (32.6) 324 (29.5) 0.210
No 509 (66.8) 763 (69.4)
Unknown 5 (0.7) 13 (1.2)
Peripheral vascular disease (five studies)
Yes 92 (16.2) 123 (14.9) 0.001
No 471 (82.9) 670 (80.9)
Unknown 5 (0.9) 35 (4.2)
Transient ischemic attack (eight studies)
Yes 82 (12.4) 22 (2.3) 0.042
No 566 (85.9) 865 (89.0)
Unknown 11 (1.7) 22 (2.3)
Diabetes (four studies)
Yes 49 (23.0) 50 (19.5) 0.648
No 163 (76.5) 205 (80.1)
Unknown 1 (0.5) 1 (0.4)
Dementia (three studies)
Yes 13 (5.7) 24 (8.1) 0.520
No 192 (84.2) 241 (80.9)
Unknown 23 (10.1) 33 (11.1)
Smoking (eight studies)
Never 319 (43.9) 804 (78.5) <0.001
Current 145 (19.9) 92 (9.0)
(continued)
Table 1. (Continued)
Characteristic
Women,
n (%) Men, n (%) p
Former 209 (28.8) 39 (3.8)
Unknown 54 (7.4) 89 (9.7)
Alcohol use (six studies)
Nondrinkers 134 (37.0) 269 (59.4) <0.001
Not heavy drinkers 70 (19.3) 57 (12.6)
Heavy drinkers 90 (25.1) 51 (11.3)
Ex-drinkers 22 (6.1) 16 (3.5)
Unknown 45 (12.4) 60 (13.3)
Stroke-related factors
Hospital admission (nine studies)
Yes 737 (96.7) 1,064 (96.7) 0.992
No 25 (3.3) 36 (3.3)
Time to hospital arrival (six studies)
£4.5 hours 61 (18.9) 121 (26.1) 0.050
>4.5–24 hours 112 (34.7) 157 (33.9)
>24 hours 24 (7.4) 21 (4.5)
Unknown 126 (39.0) 164 (35.4)
Stroke severity
Mean (SD) NIHSS score (five
studies)
9.1 (8.1) 10.8 (8.5) 0.029
Mean (SD) GCS score, reversed
(two studies)
3.3 (2.9) 3.6 (3.1) 0.402
Loss of consciousness (five studies)
Yes 179 (27.8) 272 (29.7) 0.611
No 434 (67.3) 595 (64.9)
Unknown 32 (5.0) 50 (5.5)
Medications at discharge
Antiplatelet agents (three studies)
Yes 108 (44.3) 176 (53.3) 0.040
No 136 (55.7) 152 (46.1)
Unknown 0 (0) 2 (0.6)
Anticoagulant agent (three studies)
Yes 71 (32.7) 71 (25.7) 0.146
No 143 (65.9) 197 (71.4)
Unknown 3 (1.4) 8 (2.9)
Bold denotes statistically significant results.
BI, Barthel Index; GCS, Glasgow Coma Scale; mRS, modified Rankin scale;
NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation.
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likely to receive anticoagulation therapy at discharge.
However, evidence from the literature was not consis-
tent for either Western44–47 or Asian countries.11,48,49
Use of warfarin at discharge was less in women than
in men in Get With The Guidelines-Stroke program47
and the Swedish Risk-Stroke hospital-based registry,44
whereas in studies from the Canadian stroke registry45
and Medicare participants in Michigan, there were no
sex differences.46 This might be due to the fact that
current evidence on appropriateness of anticoagula-
tion is controversial in people with acute IS who
have AF. The American Heart Association/American
Stroke Association does not recommend anticoagu-
lation for treatment of acute IS because of lack of
benefit.50–52 Whereas evidence from studies with AF
participants suggested that women, especially those
aged ‡75 years, most benefit from anticoagulation
therapy.53,54 Similarly, it has been reported that
women with acute coronary syndrome were less likely
to receive evidence-based acute treatment and medical
therapies for secondary prevention.55 However, the
reasons for these disparities were largely unknown.56
Potential explanations include sex differences in eligi-
bility for therapy, clinical contraindications, and other
clinical factors.57
Women with IS who have AF tended to have more
severe strokes than men, which could be explained by
older age and higher vascular burden. One large
population-based study36 that included *40,000 pa-
tients provided evidence that the major risk factor as-
sociated with stroke was advanced age, but that
female sex was the major risk factor among partici-
pants with AF. Older participants (‡75 years) were
the most vulnerable population. This group has the
highest rates of AF and the greatest risk of stroke.
Women tend to have much higher vascular burden,
reflected as a higher mean CHADS2 score and, there-
fore, they more often suffer larger strokes associated
with severe neurological effects depending on more
large vessel occlusions.
Our study has several strengths. This is the first IPD
meta-analysis of population-based studies to explore
the magnitude of sex difference in both short- and
long-term mortality in participants with IS who have
AF. The data come from high-quality and generaliz-
able studies free of the limitations of hospital-based
or convenience samples. We have synthesized all the
currently available evidence by pooling IPD and
meta-analysis results. However, several limitations
need to be noted. There is considerable heterogeneity
in AF prevalence, which might be due to multiple fac-
tors such as time, self-reported versus diagnosed, and
ethnic differences. Second, some potential confounding
factors were not measured including hormonal, social,
and some demographic factors, particularly race or eth-
nicity. Third, AF might be underestimated in this study.
It was self-reported in two included studies and
also there could be underascertainment when relying
on hospital records (as absence in the medical record
does not necessarily equate to absence of the risk fac-
tor). We had no information whether the diagnosis
of AF was concomitant to IS, previously, or newly di-
agnosed. Furthermore, the diagnosis of IS was not al-
ways imaging based. A merely clinical-based diagnosis
of IS could be less accurate. Both first-ever and recur-
rent IS were included, and prognosis of recurrent IS
can be different, which might impact the general-
izability of the study. In addition, some of the in-
cluded studies in the IPD were conducted in the late
1990s and in that the populations were largely Cauca-
sian. Diagnostic techniques for AF have improved
from 1990 to nowadays, as well as the management
of AF. This might have impacted prognosis of IS
over time. However, we conducted a systematic review
to synthesize the most updated published data and
pooled the aggregated data with IPD where possible
to make sure the data were relevant to current clinical
practice.
In conclusion, the poorer outcome in women with IS
and AF was mostly attributable to prestroke factors.
More reliable evidence is needed to understand sex dis-
parities in evidence-based care for secondary preven-
tion especially anticoagulation. To better understand
the clinical differences observed in presentation, treat-
ment, and outcome of IS and AF in men and women,
we suggest future population-based studies collect in-
formation on a range of reasons including socioeco-
nomic factors, barriers to access medications, and
biomarkers for biological differences that might ex-
plain these differences.
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